Provectus (PVCT) CEO converts 2025 note into Series D-1 preferred stock

Rhea-AI Filing Summary

Provectus Biopharmaceuticals CEO Edward Pershing converted debt into equity-linked securities. On January 30, 2026, an 8% unsecured convertible promissory note called the 2025 Note converted into 37,744 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.

Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on June 20, 2026 unless converted earlier under its terms. After this transaction, Pershing directly beneficially owned 2,578,867 shares of Series D-1 Convertible Preferred Stock.

Insider Trade Summary

37,744 shares exercised/converted

Mixed 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note	0	$0.00	--
Exercise	Series D-1 Convertible Preferred Stock	37,744	$0.00	--

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct); Series D-1 Convertible Preferred Stock — 2,578,867 shares (Direct)

Footnotes (1)

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On January 30, 2026, the 2025 Note was converted into 37,744 shares of Series D-1 Preferred Stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	01/30/2026		M			$100,000	01/30/2025	01/30/2026	Series D-1 Convertible Preferred Stock(3)(4)	37,744	$0	$1,280,000	D
Series D-1 Convertible Preferred Stock	(1)	01/30/2026		M		37,744		01/30/2026	(2)	Common Stock	377,440	$0	2,578,867	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On January 30, 2026, the 2025 Note was converted into 37,744 shares of Series D-1 Preferred Stock.

	/s/ Edward Pershing	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVCT CEO Edward Pershing report?

Edward Pershing reported conversion of the 8% unsecured 2025 Note into 37,744 shares of Series D-1 Convertible Preferred Stock on January 30, 2026. This reflects a shift from debt to equity-linked securities directly held by the CEO.

How many Provectus Series D-1 shares did the 2025 Note convert into?

The 2025 Note converted into 37,744 shares of Series D-1 Convertible Preferred Stock. The conversion occurred automatically at a price of $2.862 per share, in line with the terms of Provectus Biopharmaceuticals’ 2025 Financing.

How is Series D-1 Convertible Preferred Stock linked to PVCT common stock?

Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Provectus common stock. This creates a direct equity linkage, as preferred holders can ultimately receive common shares under the stated conversion terms.

When will the PVCT Series D-1 Preferred Stock automatically convert?

The Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026. It may also convert earlier according to the Certificate of Designation governing the preferred stock’s conversion terms.

How many Series D-1 Convertible Preferred shares does the PVCT CEO own after this transaction?

Following the reported transaction, Edward Pershing beneficially owned 2,578,867 shares of Series D-1 Convertible Preferred Stock. This total reflects his direct holdings after the 37,744-share issuance from converting the 2025 Note.

What was the conversion price of the PVCT 2025 Note into preferred stock?

The 8% unsecured 2025 Note converted into Series D-1 Convertible Preferred Stock at $2.862 per share. This fixed conversion price applied to both voluntary conversion rights and the automatic conversion that occurred twelve months after the note’s issue date.